Muscle Invasive Bladder Urothelial Carcinoma Clinical Trials

8 recruiting

Muscle Invasive Bladder Urothelial Carcinoma Trials at a Glance

14 actively recruiting trials for muscle invasive bladder urothelial carcinoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in New York, Clive, and Ankeny. Lead sponsors running muscle invasive bladder urothelial carcinoma studies include National Cancer Institute (NCI), IRCCS San Raffaele, and Fox Chase Cancer Center.

Browse muscle invasive bladder urothelial carcinoma trials by phase

Treatments under study

About Muscle Invasive Bladder Urothelial Carcinoma Clinical Trials

Looking for clinical trials for Muscle Invasive Bladder Urothelial Carcinoma? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscle Invasive Bladder Urothelial Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscle Invasive Bladder Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled124 locationsNCT06770582
Recruiting
Phase 3

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
NRG Oncology486 enrolled211 locationsNCT07097142
Recruiting
Phase 1

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaLocalized Muscle Invasive Bladder Urothelial Carcinoma
Shilpa Gupta, MD20 enrolled1 locationNCT05833867
Recruiting
Phase 1

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448
Recruiting
Not Applicable

Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial

Localized Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of Washington100 enrolled1 locationNCT07302230
Recruiting
Phase 2

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma
Matthew Galsky47 enrolled5 locationsNCT06809140
Recruiting

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Urothelial CarcinomaMuscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
Fox Chase Cancer Center92 enrolled2 locationsNCT06396533
Recruiting

Pan-tumor MRD Study

Esophageal CancerMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)+4 more
Paradigm Health1,350 enrolled2 locationsNCT06605404
Recruiting
Phase 2

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Muscle-Invasive Bladder CarcinomaMuscle Invasive Bladder Urothelial Carcinoma
Yung NA20 enrolled1 locationNCT06257017
Recruiting
Phase 1

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University18 enrolled1 locationNCT06766266
Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder CancerBladder NeoplasmNon Muscle Invasive Bladder Cancer+8 more
IRCCS San Raffaele20,000 enrolled1 locationNCT06167356
Recruiting

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy

Muscle-Invasive Bladder CarcinomaBladder CancerMuscle Invasive Bladder Urothelial Carcinoma+14 more
IRCCS San Raffaele4,000 enrolled1 locationNCT06170177